Zeiss Invests in Maculaser to Advance Temperature-Controlled Retinal Laser Therapy

Published on June 2, 2026
OBERKOCHEN, Germany—Zeiss Ventures, the corporate venture capital arm of the Zeiss Group, has announced its participation in the latest funding round of Maculaser, a Finnish medtech company developing a non-damaging, temperature-controlled retinal laser therapy. The funding round, co-led by Zeiss Ventures and M2care, will support Maculaser’s plan to initiate clinical development for its personalized retinal laser treatment. Maculaser specializes in advanced laser treatments for retinal diseases, particularly age-related macular degeneration (AMD) and diabetic maculopathy, the company advised.
Continue reading on website
Other news

Cure Blindness Project Releases Record-Breaking 2025 Impact Report

June 2, 2026
NORWICH, Vt.—Cure Blindness Project has released its 2025 Impact Report, highlighting a record-breaking year in the organization’s global effort to eliminate avoidable blindness. This report captures a period of unprecedented research and impact, according to the Cure Blindness Project, which includes more than 315,000 sight-restoring surgeries delivered across the organization’s global network, r

University of Miami Miller School of Medicine Names Pradeep Y. Ramulu, MD, MHS, Ph.D., Chair of Ophthalmology and Bascom Palmer Eye Institute

June 2, 2026
MIAMI—The University of Miami School of Medicine has announced the appointment of Pradeep Y. Ramulu, MD, MHS, Ph.D., as chair of the department of ophthalmology and the Bascom Palmer Eye Institute, effective August 3, 2026. Dr. Ramulu is a Bascom Palmer alumnus who “returns to lead the institution where his career in glaucoma was shaped, bringing with him nearly two decades of transformative clini